LYTIR

Company · KRRO

Korro Bio, Inc.

Nasdaq's symbol directory lists KRRO on Nasdaq as “Korro Bio, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 5 occasions ($964K); insiders sold on 20 occasions ($6.4M); 8 planned-sale notices; 6 filings by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $964K in total; Insider sales: $6.4M in total.Jun: Insider sales $2.6MJul: Insider sales $1.5MAug: Insider purchases $79KAug: Insider sales $496KSep: Insider sales $786KOct: Insider purchases $885KNov: Insider sales $974KDecJanFebMarAprMayJunJulAugSepOctNov$885K$2.6M
Insider purchases above the line: $964KInsider sales below: $6.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. FORMELA JEAN FRANCOIS sold on 12 days all under a 10b5-1 plan latest Nov 12, 2026 sold $6.1M
  2. Lynx1 Capital Management LP bought on 5 days latest Oct 26, 2026 bought $964K
  3. Dolan Oliver, Senior Vice President, Finance sold on 4 days 3 of them under a 10b5-1 plan latest Sep 11, 2026 sold $136K
  4. Cerio Jeffrey, General Counsel sold on 1 day latest Jun 16, 2026 sold $72K
  5. Aiyar Ram, President and CEO sold on 1 day latest Aug 4, 2026 sold $63K
  6. Vincent Loic A, Chief Scientific Officer sold on 1 day latest Jun 16, 2026 sold $37K
  7. Chappell Todd, Chief Operating Officer sold on 1 day latest Jun 16, 2026 sold $34K
Every trade (25)
  1. SELLFORMELA JEAN FRANCOIS sold Nov 12, 2026 40,045 shares 2 legs combined 10b5-1 plan (scheduled) filing $573K
  2. SELLFORMELA JEAN FRANCOIS sold Nov 11, 2026 26,587 shares 4 legs combined 10b5-1 plan (scheduled) filing $401K
  3. BUYLynx1 Capital Management LP bought Oct 26, 2026 25,124 shares filing $295K
  4. BUYLynx1 Capital Management LP bought Oct 23, 2026 2,510 shares filing $30K
  5. BUYLynx1 Capital Management LP bought Oct 22, 2026 52,175 shares 2 legs combined filing $559K
  6. SELLFORMELA JEAN FRANCOIS sold Sep 14, 2026 38,490 shares 2 legs combined 10b5-1 plan (scheduled) filing $543K
  7. SELLFORMELA JEAN FRANCOIS sold Sep 11, 2026 10,200 shares 2 legs combined 10b5-1 plan (scheduled) filing $143K
  8. SELLDolan Oliver, Senior Vice President, Finance sold Sep 11, 2026 5 shares 10b5-1 plan (scheduled) filing $69
  9. SELLDolan Oliver, Senior Vice President, Finance sold Sep 9, 2026 6 shares 10b5-1 plan (scheduled) filing $82
  10. SELLDolan Oliver, Senior Vice President, Finance sold Sep 8, 2026 7,347 shares 10b5-1 plan (scheduled) filing $99K
  11. SELLFORMELA JEAN FRANCOIS sold Aug 26, 2026 300 shares 2 legs combined 10b5-1 plan (scheduled) filing $4K
  12. SELLFORMELA JEAN FRANCOIS sold Aug 19, 2026 28,468 shares 2 legs combined 10b5-1 plan (scheduled) filing $399K
  13. SELLFORMELA JEAN FRANCOIS sold Aug 11, 2026 2,143 shares 2 legs combined 10b5-1 plan (scheduled) filing $30K
  14. BUYLynx1 Capital Management LP bought Aug 10, 2026 1,462 shares filing $19K
  15. BUYLynx1 Capital Management LP bought Aug 6, 2026 5,222 shares filing $60K
  16. SELLAiyar Ram, President and CEO sold Aug 4, 2026 5,802 shares filing $63K
  17. SELLFORMELA JEAN FRANCOIS sold Jul 6, 2026 9,323 shares 2 legs combined 10b5-1 plan (scheduled) filing $130K
  18. SELLFORMELA JEAN FRANCOIS sold Jul 2, 2026 100,700 shares 2 legs combined 10b5-1 plan (scheduled) filing $1.4M
  19. SELLFORMELA JEAN FRANCOIS sold Jun 24, 2026 48,438 shares 4 legs combined 10b5-1 plan (scheduled) filing $707K
  20. SELLFORMELA JEAN FRANCOIS sold Jun 23, 2026 119,005 shares 2 legs combined 10b5-1 plan (scheduled) filing $1.7M
  21. SELLFORMELA JEAN FRANCOIS sold Jun 22, 2026 3,962 shares 2 legs combined 10b5-1 plan (scheduled) filing $55K
  22. SELLCerio Jeffrey, General Counsel sold Jun 16, 2026 6,609 shares filing $72K
  23. SELLVincent Loic A, Chief Scientific Officer sold Jun 16, 2026 3,418 shares filing $37K
  24. SELLDolan Oliver, Senior Vice President, Finance sold Jun 16, 2026 3,383 shares filing $37K
  25. SELLChappell Todd, Chief Operating Officer sold Jun 16, 2026 3,168 shares filing $34K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. Atlas Venture Fund XI, L.P. filed Nov 12, 2026 Shareholder 55,201 shares planned sale date 11/12/2026 filing $795K
  2. Atlas Venture Opportunity Fund II, L.P. filed Nov 12, 2026 Shareholder 11,431 shares planned sale date 11/12/2026 filing $165K
  3. Atlas Venture Fund XI, L.P. filed Sep 14, 2026 Shareholder 31,888 shares planned sale date 09/14/2026 filing $440K
  4. Atlas Venture Opportunity Fund II, L.P. filed Sep 14, 2026 Shareholder 6,602 shares planned sale date 09/14/2026 filing $91K
  5. Atlas Venture Fund XI, L.P. filed Sep 11, 2026 Shareholder 8,450 shares planned sale date 09/11/2026 filing $110K
  6. Atlas Venture Opportunity Fund II, L.P. filed Sep 11, 2026 Shareholder 1,750 shares planned sale date 09/11/2026 filing $23K
  7. Dolan Oliver filed Sep 11, 2026 Officer 5 shares planned sale date 09/11/2026 filing $69
  8. Dolan Oliver filed Sep 9, 2026 Officer 6 shares planned sale date 09/09/2026 filing $82

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Venrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive filing 9.9%
  2. Adage Capital Management, L.P. filed Nov 12, 2026 Schedule 13G passive filing 6.79%
  3. BlackRock, Inc. filed Oct 27, 2026 Schedule 13G/A passive 717,813 shares filing 4.9%
  4. BALYASNY ASSET MANAGEMENT L.P. filed Aug 14, 2026 Schedule 13G/A passive filing 6.6%
  5. Atlas Venture Fund XI, L.P. filed Aug 4, 2026 Schedule 13D/A may seek influence 706,556 shares filing 4.9%
  6. BlackRock, Inc. filed Jul 29, 2026 Schedule 13G passive 747,546 shares filing 5.2%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Termination of a material definitive agreement; Results of operations and financial condition filing Nov 5, 2026
  2. Other events filing Oct 22, 2026
  3. Other events filing Oct 5, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.